Mechanism of Daphnetin on Inhibiting ACE2 Expression and Preventing SARS-CoV-2 Infection

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300077554

Enrollment

Unknown

Registered

2023-11-13

Start date

2023-11-13

Completion date

Unknown

Last updated

2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Self control of volunteers before and after medication:Oral Daphne Capsules

Eligibility

Sex/Gender

All

Age

22 Years to 50 Years

Inclusion criteria

Inclusion criteria: On campus teachers and students of Wannan Medical College, aged between 30 and 40, 3 males and 3 females, healthy individuals, BMI index 18.5-24.99

Exclusion criteria

Exclusion criteria: Postoperative and bleeding prone; Liver and kidney dysfunction; Severe hypertension; Pregnant and lactating women; Individuals who are allergic to Daphne capsules.

Design outcomes

Primary

Measure	Time frame
ACE2;	—

Countries

China

Contacts

Public ContactXiaohui Xu

Wannan Medical College

xhxu@wnmc.edu.cn+86 186 5535 0863

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026